pyridoxine has been researched along with Foot Dermatoses in 8 studies
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).
Foot Dermatoses: Skin diseases of the foot, general or unspecified.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether concurrent pyridoxine therapy can prevent the development of hand-foot syndrome (HFS) in patients being treated with capecitabine." | 9.14 | Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. ( Chang, HM; Chun, YJ; Kang, YK; Kim, MS; Kim, TW; Lee, JL; Lee, SS; Lee, SY; Ryu, MH; Yoon, DH, 2010) |
| "Prophylactic pyridoxine was given to 38 patients receiving capecitabine (alone or in combination with cyclophosphamide) for metastatic breast cancer and compared with historical data from 40 patients receiving capecitabine without pyridoxine in our clinic." | 7.76 | Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. ( Fujita, T; Hayashi, H; Iwata, H; Kimura, M; Kondo, N; Toyama, T; Tsunoda, N; Tsuzuki, N; Yamashita, H; Yamashita, T; Yoshimoto, N, 2010) |
| "The limiting toxicity of low dose continuous infusion 5-fluorouracil (200-300 mg/m2/day) is often palmar-plantar erythrodysesthesia (PPE)." | 7.68 | Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. ( Dahlberg, S; Fabian, CJ; Giri, S; Molina, R; Slavik, M; Stephens, R, 1990) |
| "To determine whether concurrent pyridoxine therapy can prevent the development of hand-foot syndrome (HFS) in patients being treated with capecitabine." | 5.14 | Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. ( Chang, HM; Chun, YJ; Kang, YK; Kim, MS; Kim, TW; Lee, JL; Lee, SS; Lee, SY; Ryu, MH; Yoon, DH, 2010) |
| "Patients with histologically confirmed breast cancer or colorectal cancer receiving single agent capecitabine started at 2000 to 2500 mg/m(2) daily from day 1 to 14 every 3 weeks were randomly assigned to receive 200 mg or 400 mg daily of pyridoxine for PPE prophylaxis." | 5.14 | Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. ( Chalermchai, T; Sriuranpong, V; Suwanrusme, H; Tantiphlachiva, K; Voravud, N, 2010) |
| "Prophylactic pyridoxine was given to 38 patients receiving capecitabine (alone or in combination with cyclophosphamide) for metastatic breast cancer and compared with historical data from 40 patients receiving capecitabine without pyridoxine in our clinic." | 3.76 | Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. ( Fujita, T; Hayashi, H; Iwata, H; Kimura, M; Kondo, N; Toyama, T; Tsunoda, N; Tsuzuki, N; Yamashita, H; Yamashita, T; Yoshimoto, N, 2010) |
| "The limiting toxicity of low dose continuous infusion 5-fluorouracil (200-300 mg/m2/day) is often palmar-plantar erythrodysesthesia (PPE)." | 3.68 | Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. ( Dahlberg, S; Fabian, CJ; Giri, S; Molina, R; Slavik, M; Stephens, R, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yoshimoto, N | 1 |
| Yamashita, T | 1 |
| Fujita, T | 1 |
| Hayashi, H | 1 |
| Tsunoda, N | 1 |
| Kimura, M | 1 |
| Tsuzuki, N | 1 |
| Yamashita, H | 1 |
| Toyama, T | 1 |
| Kondo, N | 1 |
| Iwata, H | 1 |
| Kang, YK | 1 |
| Lee, SS | 1 |
| Yoon, DH | 1 |
| Lee, SY | 1 |
| Chun, YJ | 1 |
| Kim, MS | 1 |
| Ryu, MH | 1 |
| Chang, HM | 1 |
| Lee, JL | 1 |
| Kim, TW | 1 |
| von Gruenigen, V | 1 |
| Frasure, H | 1 |
| Fusco, N | 1 |
| DeBernardo, R | 1 |
| Eldermire, E | 1 |
| Eaton, S | 1 |
| Waggoner, S | 1 |
| Chalermchai, T | 1 |
| Tantiphlachiva, K | 1 |
| Suwanrusme, H | 1 |
| Voravud, N | 1 |
| Sriuranpong, V | 1 |
| von Moos, R | 1 |
| Thuerlimann, BJ | 1 |
| Aapro, M | 1 |
| Rayson, D | 1 |
| Harrold, K | 1 |
| Sehouli, J | 1 |
| Scotte, F | 1 |
| Lorusso, D | 1 |
| Dummer, R | 1 |
| Lacouture, ME | 1 |
| Lademann, J | 1 |
| Hauschild, A | 1 |
| Rossi, D | 1 |
| Catalano, G | 1 |
| Vukelja, SJ | 1 |
| Baker, WJ | 1 |
| Burris, HA | 1 |
| Keeling, JH | 1 |
| Von Hoff, D | 1 |
| Fabian, CJ | 1 |
| Molina, R | 1 |
| Slavik, M | 1 |
| Dahlberg, S | 1 |
| Giri, S | 1 |
| Stephens, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-Blind Phase III Study of Pyridoxine vs Placebo for the Prevention of Capecitabine-induced Hand-Foot Syndrome[NCT00446147] | Phase 3 | 389 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552] | Phase 3 | 870 participants (Anticipated) | Interventional | 2013-08-19 | Recruiting | ||
| Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Bre[NCT01367028] | Phase 2 | 100 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A total administered dose of capecitabine until the development of grade 2 or higher hand-foot syndrome during the chemotherapy. (NCT00446147)
Timeframe: Up to 2 years
| Intervention | miligram per square meter (Median) |
|---|---|
| Placebo | 70000 |
| Pyridoxine | 70000 |
Number of patients with any grade of hand-foot syndrome (NCT00446147)
Timeframe: Up to 2 years
| Intervention | participants (Number) |
|---|---|
| Placebo | 55 |
| Pyridoxine | 57 |
3 trials available for pyridoxine and Foot Dermatoses
| Article | Year |
|---|---|
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou | 2010 |
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou | 2010 |
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou | 2010 |
Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dou | 2010 |
A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients.
Topics: Aged; Antineoplastic Agents; Double-Blind Method; Doxorubicin; Endometrial Neoplasms; Female; Foot D | 2010 |
Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Col | 2010 |
5 other studies available for pyridoxine and Foot Dermatoses
| Article | Year |
|---|---|
Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deo | 2010 |
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.
Topics: Adrenal Cortex Hormones; Dermatologic Agents; Doxorubicin; Drug Eruptions; Erythema; Foot Dermatoses | 2008 |
Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Clinical Trials as Topic; Doxorubicin; Erythema; | 2007 |
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Erythema; Female; Foot Dermatoses; Hand Dermatoses; Hu | 1993 |
Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.
Topics: Colonic Neoplasms; Edema; Erythema; Fluorouracil; Follow-Up Studies; Foot Dermatoses; Hand Dermatose | 1990 |